{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:54:03Z","timestamp":1790409243817,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies and combinations are therefore required to improve outcomes. B cell maturation antigen (BCMA)-targeted biologics have emerged as an important new area of therapeutics for relapsed multiple myeloma. The two-part ALGONQUIN trial evaluated various doses and schedules of the anti-BCMA antibody\u2013drug conjugate belantamab mafodotin plus pomalidomide and dexamethasone for patients who are lenalidomide refractory and proteosome inhibitor exposed. The primary endpoints, including evaluating dose-limiting toxicities, establishing the recommended Part 2 dose (RP2D) and overall response rate for patients treated at the RP2D, were met. Secondary efficacy endpoints included progression-free survival and overall survival. Patients treated on study (<jats:italic>N<\/jats:italic>\u2009=\u200987) had a median of three previous regimens and 55.2% were triple-class refractory. At the RP2D the most common adverse events were decrease in best-corrected visual acuity (71.1%), keratopathy (65.8%), fatigue (57.9%), infection (47.4%; 7.9% grade \u22653), neutropenia (39.5%) and thrombocytopenia (39.5%). For RP2D patients (<jats:italic>n<\/jats:italic>\u2009=\u200938), the overall response rate was 85.3%, \u2265very good partial response 75.7% and estimated two-year progression-free survival 52.8% (95% confidence interval, 33.9% to 82.4%), at a median follow-up of 13.9\u2009months. The RP2D schedule was associated with manageable antibody\u2013drug conjugate-associated corneal adverse events and improved tolerability without compromising efficacy. Belantamab mafodotin plus pomalidomide and dexamethasone induced durable responses with promising overall survival in relapsed multiple myeloma, the results of which are yet to be confirmed in the phase 3 DREAMM-8 study. ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT03715478\">NCT03715478<\/jats:ext-link>.<\/jats:p>","DOI":"10.1038\/s41591-023-02703-y","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T11:02:08Z","timestamp":1704366128000},"page":"543-551","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1\/2 trial"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-6352","authenticated-orcid":false,"given":"Suzanne","family":"Trudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arleigh","family":"McCurdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Louzada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Parkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami","family":"Kotb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hira","family":"Mian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibraheem","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiandong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniba","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3922-3215","authenticated-orcid":false,"given":"Engin","family":"Gul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7201-4642","authenticated-orcid":false,"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"2703_CR1","doi-asserted-by":"publisher","first-page":"3128","DOI":"10.1182\/blood-2013-10-535088","volume":"123","author":"YT Tai","year":"2014","unstructured":"Tai, Y. T. et al. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood 123, 3128\u20133138 (2014).","journal-title":"Blood"},{"key":"2703_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial, S. et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 21, 207\u2013221 (2020).","journal-title":"Lancet Oncol."},{"key":"2703_CR3","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel, J. S. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 14, 1055\u20131066 (2013).","journal-title":"Lancet Oncol."},{"key":"2703_CR4","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1182\/blood.V99.11.4079","volume":"99","author":"N Mitsiades","year":"2002","unstructured":"Mitsiades, N. et al. Biologic sequelae of nuclear factor-\u03baB blockade in multiple myeloma: therapeutic applications. Blood 99, 4079\u20134086 (2002).","journal-title":"Blood"},{"key":"2703_CR5","doi-asserted-by":"publisher","first-page":"380","DOI":"10.4049\/jimmunol.163.1.380","volume":"163","author":"LG Corral","year":"1999","unstructured":"Corral, L. G. et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-\u03b1. J. Immunol. 163, 380\u2013386 (1999).","journal-title":"J. Immunol."},{"key":"2703_CR6","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1182\/blood.V98.1.210","volume":"98","author":"FE Davies","year":"2001","unstructured":"Davies, F. E. et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98, 210\u2013216 (2001).","journal-title":"Blood"},{"key":"2703_CR7","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","volume":"140","author":"N Reddy","year":"2008","unstructured":"Reddy, N. et al. Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 140, 36\u201345 (2008).","journal-title":"Br. J. Haematol."},{"key":"2703_CR8","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/leu.2015.240","volume":"30","author":"H Jiang","year":"2016","unstructured":"Jiang, H. et al. SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 30, 399\u2013408 (2016).","journal-title":"Leukemia"},{"key":"2703_CR9","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal, M. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet 394, 2096\u20132107 (2019).","journal-title":"Lancet"},{"key":"2703_CR10","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S1470-2045(21)00128-5","volume":"22","author":"MA Dimopoulos","year":"2021","unstructured":"Dimopoulos, M. A. et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 801\u2013812 (2021).","journal-title":"Lancet Oncol."},{"key":"2703_CR11","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1038\/s41375-020-0813-1","volume":"34","author":"DS Siegel","year":"2020","unstructured":"Siegel, D. S. et al. Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment. Leukemia 34, 3286\u20133297 (2020).","journal-title":"Leukemia"},{"key":"2703_CR12","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1200\/JCO.21.02815","volume":"41","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for relapsed\/refractory multiple myeloma: final overall survival analysis from the randomized phase II ELOQUENT-3 trial. J. Clin. Oncol. 41, 568\u2013578 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR13","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10637-017-0520-6","volume":"36","author":"JC Masters","year":"2018","unstructured":"Masters, J. C. et al. Clinical toxicity of antibody drug conjugates: a meta-analysis of payloads. Invest. New Drugs 36, 121\u2013135 (2018).","journal-title":"Invest. New Drugs"},{"key":"2703_CR14","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","volume":"27","author":"MQ Lacy","year":"2009","unstructured":"Lacy, M. Q. et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. J. Clin. Oncol. 27, 5008\u20135014 (2009).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G. et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl. J. Med. 387, 132\u2013147 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2703_CR16","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon, T. et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 1582\u20131596 (2021).","journal-title":"Lancet Oncol."},{"key":"2703_CR17","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1016\/S1470-2045(21)00428-9","volume":"22","author":"P Moreau","year":"2021","unstructured":"Moreau, P. et al. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 22, 1378\u20131390 (2021).","journal-title":"Lancet Oncol."},{"key":"2703_CR18","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees, P. M. et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 136, 936\u2013945 (2020).","journal-title":"Blood"},{"key":"2703_CR19","doi-asserted-by":"publisher","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","volume":"9","author":"H Goldschmidt","year":"2022","unstructured":"Goldschmidt, H. et al. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial. Lancet Haematol. 9, e810\u2013e821 (2022).","journal-title":"Lancet Haematol."},{"key":"2703_CR20","doi-asserted-by":"publisher","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","volume":"10","author":"MA Dimopoulos","year":"2023","unstructured":"Dimopoulos, M. A. et al. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study. Lancet Haematol. 10, e801\u2013e812 (2023).","journal-title":"Lancet Haematol."},{"key":"2703_CR21","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/10428194.2022.2030477","volume":"63","author":"NJ Bahlis","year":"2022","unstructured":"Bahlis, N. J. et al. Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leuk. Lymphoma 63, 1407\u20131417 (2022).","journal-title":"Leuk. Lymphoma"},{"key":"2703_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/S1470-2045(22)00019-5","volume":"23","author":"PG Richardson","year":"2022","unstructured":"Richardson, P. G. et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study. Lancet Oncol. 23, 416\u2013427 (2022).","journal-title":"Lancet Oncol."},{"key":"2703_CR23","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos, M. A. et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N. Engl. J. Med. 379, 1811\u20131822 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2703_CR24","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson, P. G. et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 20, 781\u2013794 (2019).","journal-title":"Lancet Oncol."},{"key":"2703_CR25","doi-asserted-by":"publisher","first-page":"8018","DOI":"10.1200\/JCO.2021.39.15_suppl.8018","volume":"39","author":"D White","year":"2021","unstructured":"White, D. et al. Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM). J. Clin. Oncol. 39, 8018\u20138018 (2021).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR26","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","volume":"127","author":"RC Baz","year":"2016","unstructured":"Baz, R. C. et al. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma. Blood 127, 2561\u20132568 (2016).","journal-title":"Blood"},{"key":"2703_CR27","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1182\/blood-2022-162440","volume":"140","author":"NJ Bahlis","year":"2022","unstructured":"Bahlis, N. J. et al. Efficacy and safety of elranatamab in patients with relapsed\/refractory multiple myeloma na\u00efve to B-cell maturation antigen (BCMA)-directed therapies: results from cohort A of the Magnetismm-3 study. Blood 140, 391\u2013393 (2022).","journal-title":"Blood"},{"key":"2703_CR28","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2703_CR29","doi-asserted-by":"publisher","first-page":"8039","DOI":"10.1200\/JCO.2023.41.16_suppl.8039","volume":"41","author":"MH Tomasson","year":"2023","unstructured":"Tomasson, M. H. et al. Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): extended follow up and biweekly administration from the MagnetisMM-3 study. J. Clin. Oncol. 41, 8039\u20138039 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR30","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"P Moreau","year":"2023","unstructured":"Moreau, P. et al. Long-term follow-up from MajesTEC-1 of teclistamab, a B-cell maturation antigen (BCMA) x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). J. Clin. Oncol. 41, 8011\u20138011 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR31","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1182\/blood-2022-159711","volume":"140","author":"E Searle","year":"2022","unstructured":"Searle, E. et al. Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase 1b, multicohort study. Blood 140, 394\u2013396 (2022).","journal-title":"Blood"},{"key":"2703_CR32","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero, P. et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N. Engl. J. Med. 388, 1002\u20131014 (2023).","journal-title":"N. Engl. J. Med."},{"key":"2703_CR33","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1200\/JCO.22.00842","volume":"41","author":"T Martin","year":"2023","unstructured":"Martin, T. et al. Ciltacabtagene autoleucel, an anti\u2013B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up. J. Clin. Oncol. 41, 1265\u20131274 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR34","doi-asserted-by":"publisher","first-page":"8009","DOI":"10.1200\/JCO.2023.41.16_suppl.8009","volume":"41","author":"TG Martin","year":"2023","unstructured":"Martin, T. G. et al. CARTITUDE-1 final results: phase 1b\/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed\/refractory multiple myeloma. J. Clin. Oncol. 41, 8009\u20138009 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR35","doi-asserted-by":"publisher","first-page":"LBA106","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA106","volume":"41","author":"K Yong","year":"2023","unstructured":"Yong, K. et al. First phase 3 results from CARTITUDE-4: cilta-cel versus standard of care (PVd or DPd) in lenalidomide-refractory multiple myeloma. J. Clin. Oncol. 41, LBA106\u2013LBA106 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR36","doi-asserted-by":"publisher","first-page":"e20031","DOI":"10.1200\/JCO.2023.41.16_suppl.e20031","volume":"41","author":"I Ntanasis-Stathopoulos","year":"2023","unstructured":"Ntanasis-Stathopoulos, I. et al. Ocular adverse events in transplant ineligible patients with newly diagnosed multiple myeloma treated with belantamab mafodotin plus lenalidomide\/dexamethasone from the phase 1\/2 BelaRd study. J. Clin. Oncol. 41, e20031\u2013e20031 (2023).","journal-title":"J. Clin. Oncol."},{"key":"2703_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40123-020-00280-8","volume":"9","author":"AV Farooq","year":"2020","unstructured":"Farooq, A. V. et al. Corneal epithelial findings in patients with multiple myeloma treated with antibody-drug conjugate belantamab mafodotin in the pivotal, randomized, DREAMM-2 study. Ophthalmol. Ther. 9, 889\u2013911 (2020).","journal-title":"Ophthalmol. Ther."},{"key":"2703_CR38","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02703-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02703-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02703-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T13:09:46Z","timestamp":1708434586000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02703-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2703"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02703-y","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"assertion":[{"value":"4 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: S.T. received grant support from GSK, Bristol Myers Squibb (BMS), Janssen, Pfizer, Amgen, Roche and Genentech; consulting fees from BMS, GSK and Roche; and honoraria from BMS, Janssen, Amgen, Sanofi and Pfizer. A.M. received honoraria from Celgene, Janssen, Amgen, Takeda, Sanofi and GSK. M.L.L. received research support from BMS\/Celgene and Janssen; and honoraria from BMS\/Celgene, Janssen, Gilead, AbbVie, AstraZeneca and Takeda. S.P. received consultancy honoraria from Janssen, BMS, FORUS and Apotex; study funding from GSK; and funding from BMS. D.W. received honoraria from Amgen, Antengene, BMS, FORUS Therapeutics, GSK, Janssen, Karyopharm, Pfizer, Sanofi and Takeda. M.P.C. received research support from BMS\/Celgene and Janssen; and honoraria from BMS\/Celgene, Janssen, Gilead, AbbVie, AstraZeneca and Takeda. R.K. received honoraria from Akcea Therapeutics, Amgen, BMS, Janssen, Merck, Sanofi, Celgene, Pfizer and Takeda; received research funding from Merck and Sanofi; and is a current equity holder in the private company Karyopharm. H.M. received advisory fees from Janssen, Takeda, Amgen, Pfizer, BMS, FORUS and Sanofi; received research funding from Janssen; and is supported by the early career award from Hamilton Health Sciences. I.O. participated in advisory boards for and received honoraria from Amgen, BMS, Celgene, FORUS Therapeutics, Janssen, Pfizer, Sanofi-Genzyme and Takeda; and received research funding from Janssen. J.S., A.K. and E.G. are employees of CMRG. D.R. received research funding and honoraria from, and is on the advisory board of, Janssen, BMS and Takeda; received research funding from Millennium Pharmaceuticals; and received honoraria from Amgen, Sanofi and GSK.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}